AbbVie Launches, Biogen Tweaks Alzheimer's Collaborations

Development of new Alzheimer’s disease treatments is the focus of separate collaboration agreements announced today by AbbVie and Biogen.AbbVie and Alector said they plan to develop and commercialize therapies to treat Alzheimer's and other neurodegenerative disorders using the latter’s immuno-neurology drug discovery tech platform, through a collaboration that could generate up to $225 million for Alector.Alector’s platform is designed to fight Alzheimer’s and other neur